Tonix Pharmaceuticals
TNXP
60 hedge funds and large institutions have $57M invested in Tonix Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 5 closing their positions.
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
74% more call options, than puts
Call options by funds: $951K | Put options by funds: $548K
28% more funds holding
Funds holding: 47 → 60 (+13)
14% more capital invested
Capital invested by funds: $50M → $57M (+$6.93M)
8% more ownership
Funds ownership: 18.9% → 26.9% (+8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.6M |
| 2 |
BlackRock
New York
|
+$9.69M |
| 3 |
Capital Fund Management (CFM)
Paris,
France
|
+$2.34M |
| 4 |
Millennium Management
New York
|
+$1.63M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.36M |
| 2 |
EH
Equitable Holdings
New York
|
-$379K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$255K |
| 4 |
State Board of Administration of Florida Retirement System
Tallahassee,
Florida
|
-$249K |
| 5 |
JSL
JT Stratford LLC
Gainesville,
Georgia
|
-$232K |
TNXP Hedge Fund Activity: Q3 2025 in Review
60 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q3 2025, worth a combined $57M — up 14% from $50M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TNXP positions and 5 closed out — a net gain of 13 holders — while 23 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $14.6M. The largest seller was Nuveen, cutting an estimated $1.36M.
- 60 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q3 2025, up from 47 in Q2 2025.
- Funds reported $57M of Tonix Pharmaceuticals stock for Q3 2025, up 14% quarter-over-quarter.
- 18 funds opened new Tonix Pharmaceuticals positions in Q3 2025 and 5 closed out, a net change of +13 holders.
- The largest Tonix Pharmaceuticals buyer in Q3 2025 was Vanguard Group, an estimated $14.6M added.
- The largest Tonix Pharmaceuticals seller in Q3 2025 was Nuveen, an estimated $1.36M sold.
Based on aggregated 13F filings for Q3 2025.